fispemifene fispemifene fispemifene (inn, usan) (developmental code name hm-101) is a nonsteroidal selective estrogen receptor modulator (serm) of the triphenylethylene group that was developed for the treatment of male hypogonadism but was abandoned and never marketed. it reached phase ii clinical trials for this indication before development was terminated in march 2016. the drug failed to achieve statistical significance on key effectiveness endpoints in clinical trials and was discontinued by its developer for strategic reasons. fispemifeneclinical dataother nameshm-101identifiers iupac name 2-(2-(4-((1z)-4-chloro-1,2-diphenylbut-1-enyl)phenoxy)ethoxy)ethanol cas number341524-89-8pubchem cid9954033chemspider8129643unii3vz2833v08keggd10008chemblchembl2107341chemical and physical dataformulac26h27clo3molar mass422.95 g·mol−13d model (jsmol)interactive image smiles c1=cc=c(c=c1)/c(=c(/c2=cc=cc=c2)\c3=cc=c(c=c3)occocco)/cccl inchi inchi=1s/c26h27clo3/c27-16-15-25(21-7-3-1-4-8-21)26(22-9-5-2-6-10-22)23-11-13-24(14-12-23)30-20-19-29-18-17-28/h1-14,28h,15-20h2/b26-25-key:nkztzaqikkgtdb-qplcgjkrsa-n